Back
Nuveen Core Plus Impact Fund Vs. Apellis Pharmaceuticals Industry Stock Comparison
Buy
59
NPCT
Nuveen Core Plus Impact Fund
Last Price:
11.66
Seasonality Move:
-0.71%
Sell
19
APLS
Apellis Pharmaceuticals
Last Price:
32.49
Seasonality Move:
18.8%
Buy
59
Nuveen Core Plus Impact Fund (NPCT)
is a Buy
Is Nuveen Core Plus Impact Fund a Buy, Sell or Hold?
- The current Nuveen Core Plus Impact Fund [NPCT] share price is $11.67. The Score for NPCT is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.
- NPCT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
19
Apellis Pharmaceuticals (APLS)
is a Sell
Is Apellis Pharmaceuticals a Buy, Sell or Hold?
- The current Apellis Pharmaceuticals [APLS] share price is $32.50. The Score for APLS is 19, which is 62% below its historic median score of 50, and infers higher risk than normal.
- APLS is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
NPCT Stock Price Chart
What is Nuveen Core Plus Impact Fund's stock price today?
-
The Nuveen Core Plus Impact Fund share price today is $11.67
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NPCT is experiencing buying pressure, which is a positive indicator for future bullish movement.
APLS Stock Price Chart
What is Apellis Pharmaceuticals's stock price today?
-
The Apellis Pharmaceuticals share price today is $32.50
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and APLS is experiencing slight selling pressure.
NPCT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.06 | Buy |
| Relative Strength Index (14 RSI): | 61.38 | Buy |
| Chaikin Money Flow: | 82057 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (11.47 - 11.65) | Buy |
| Bollinger Bands (100): | (10.63 - 11.53) | Buy |
APLS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.84 | Sell |
| Relative Strength Index (14 RSI): | 33.6 | Sell |
| Chaikin Money Flow: | -1084788 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (36.37 - 40.01) | Sell |
| Bollinger Bands (100): | (36.55 - 42.35) | Sell |
NPCT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 11.66 | Buy |
| 20-day SMA: | 11.59 | Buy |
| 50-day SMA: | 11.47 | Buy |
| 200-day SMA: | 10.66 | Buy |
| 8-day EMA: | 11.64 | Buy |
| 20-day EMA: | 11.59 | Buy |
| 50-day EMA: | 11.42 | Buy |
| 200-day EMA: | 10.81 | Buy |
APLS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 36.19 | Sell |
| 20-day SMA: | 38.04 | Sell |
| 50-day SMA: | 37.88 | Sell |
| 200-day SMA: | 50 | Sell |
| 8-day EMA: | 35.96 | Sell |
| 20-day EMA: | 37.21 | Sell |
| 50-day EMA: | 38.25 | Sell |
| 200-day EMA: | 45.7 | Sell |
Nuveen Core Plus Impact Fund Earnings Growth & NPCT Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Apellis Pharmaceuticals Earnings Growth & APLS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.74 per share, an increase next quarter of $0.23 per share, an increase this year of $3.28 per share, and an increase next year of $1.34 per share.
Nuveen Core Plus Impact Fund Technical Analysis
| Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Apellis Pharmaceuticals Technical Analysis
| Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||